Overview

Innovative Tendon Repair Technology Poised for Market Disruption

Market Opportunity

Large Market Gap in Tendon Repair Solutions Drives Demand

CoNextions TR Tendon Repair System

Replacing Centuries-Old Suture Methods with a Custom-Formed Sterile Implant

• Fully formed implant custom sized from pre-formed anchor plates and pre-formed dorsal plates to individual tendon thickness

• Delivered via a single-use sterile delivery system.
• Replaces tedious surgical knot-tying with a precise, repeatable mechanical deployment

Superior Clinical Outcomes vs. Standard of Care

Validated Human Trial Data Demonstrates Faster, Stronger, and Safer Repairs

2x Stronger

Strength & Safety: 2 times stronger than suture repairs, reducing ruptures and allowing potential for earlier mobility

2.2x Less Resistance

Mechanical Advantage: 2.2 times less glide resistance than suture repairs, resulting in less triggering

Suture patients were 3 times more likely than CoNextions TR patients to have significant disability at 24-week follow-up

Investment Strategy

Executing Commercial Launch and Pipeline Expansion with Strong Partner

Exclusive Distribution & Massive TAM Expansion

Scaling and Expanding Indications Through 2027

Key Advantages (Alpha)

Proprietary IP and Clinical Validation Underpin Durable Competitive Moat

Deep and Defensible Global Intellectual Property

Foundational Patents Provide Substantial Freedom to Operate and High Entry Barriers

Track Record & Economics

Established Clinical and Financial Foundations Support Growth Potential

Premium Unit Economics & Strategic M&A Potential

>90% Gross Margins Position CoNextions as a Highly Accretive Asset for Extremities Franchises

Unit Economics

• Powerful Unit Economics: $1,900 ASP vs. $144 COGS (>90% Gross Margin)

• Reimbursement Dynamics: Implants are paid out of site of service insurance. 25% of upper extremity tendon injuries fall under Worker’s Comp.

• 2024 end-user sales estimated at ~$5M

Strategic M&A Rationale

• M&A Rationale: Zero product overlap or cannibalization for acquirers—pure incremental operating profit. Plugs directly into existing orthopedic sales forces. Fully integrated manufacturer with an approved QMS ensures seamless post-merger integration.

Experienced Management Team

Executive Management

Dan Gruppo  President & Chief Executive Officer

Duraid Jwayyed  Chief Financial Officer

Attila Poka, MD  Chief Medical Officer

Roy Taylor  Vice President R&D

Cody Gehrke  Director of Operations

Jeff Barnes  Executive Chairman

Total employees: 16 

• Executive Team: Started and successfully managed multiple medical device companies with successful exits or ongoing enterprises

• Research & Development: Developed and successfully launched over 40 medical devices
• Sales & Marketing: Worldwide experienced sales and marketing executives from leading orthopedic companies

• Clinical & Quality: Extensive experience with multiple medical devices in the US and abroad, ensuring domestic and international regulatory compliance

• Operations: Experienced in manufacturing engineering and scale-up; process control

Experienced Management Team

Dan Gruppo — President & CEO

• Former Stryker executive; led upper extremity/trauma commercialization
• Expertise in scaling revenue and surgeon adoption

Duraid Jwayyed — CFO

• Leadership roles at Stryker, Eaton, Caterpillar
• Oversees finance, IR, and strategy

Dr. Erik N. Kubiak — Co-Founder, Medical Advisory Chair

• Academic surgeon; 50+ publications
• Expertise in clinical trials and product development

Jeffrey Barnes — Executive Chairman

• Managing Director, BioVentures Investors
  • Led 18 investments with multiple strategic exits

Dr. Attila Poka — Chief Medical Officer

• Renowned orthopedic trauma surgeon
• Extensive clinical and research background